ALFA Finder| Revenue growth | 22% YoY in Q1 FY27 |
|---|---|
| Margins | EBITDA margin 25% (down from 27%) |
| Order book | 200+ CT/MRI centers on order-book completion |
| Demand visibility | Strong, 76Mn+ patients served in 5 years |
| Management confidence | High on retail and PPP synergy |
Growth
Revenue grew 22% YoY to ₹2,355 Mn; EBITDA rose 12% to ₹588 Mn; PAT declined 19% to ₹166 Mn.
Outlook
Focus on cash business, scaling Rajasthan labs, and achieving 200+ CT/MRI centers on order-book completion.
Risks
Margin moderation (EBITDA margin -221 bps) due to upfront fixed costs in Rajasthan and Tamil Nadu MRI discontinuation.
Last quarter's promises, checked
Delivered
- Guided Rajasthan contribution in Q1 FY27 → delivered 22% overall revenue growth (= BEAT)
- Guided 200+ CT/MRI centers on order-book completion → delivered 190+ currently operational (= BEAT)
- Guided retail contribution to scale up → delivered 64% YoY retail revenue growth (= BEAT)
Partly delivered
- Guided reducing DSO to sub-120 days → delivered 139 days (= PARTIAL)
Missed
- Guided maintaining EBITDA margins at 28-30% → delivered 25% (= MISS)
Investor Presentation filed with BSE, NSE: KRSNAA. Summary written with AI assistance from the document.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹508.50
- Market cap
- ₹1,650 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 16.8×Sector 54.5×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa Diagnostics Convertible Warrants
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
- Value
- ₹91.75 Cr
Krsnaa Diagnostics Bags New Order from Municipal Corporation of Delhi
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
- From
- Municipal Corporation of Delhi (MCD)
- Execution
- 15 years
- diagnostic facilities
- 3.0 project sites
Krsnaa Diagnostics Earnings Call Transcript: Key Takeaways
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
- Call
- Guides 45% growth
Krsnaa Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.